Addendum: Systemic AL amyloidosis: current approach and future direction
Oncotarget
.
2023 Jul 20:14:721.
doi: 10.18632/oncotarget.28478.
Authors
Maroun Bou Zerdan
1
,
Lewis Nasr
2
,
Farhan Khalid
3
,
Sabine Allam
4
,
Youssef Bouferraa
5
,
Saba Batool
6
,
Muhammad Tayyeb
3
,
Shubham Adroja
7
,
Mahinbanu Mammadii
1
,
Faiz Anwer
8
,
Shahzad Raza
8
,
Chakra P Chaulagain
9
Affiliations
1
Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
2
University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
3
Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.
4
Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon.
5
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
6
Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA.
7
Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77094, USA.
8
Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
9
Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
PMID:
37477528
PMCID:
PMC10360921
DOI:
10.18632/oncotarget.28478
No abstract available
Publication types
Published Erratum